Goldman Sachs Group, Inc. (The) reiterated their sell rating on shares of AstraZeneca plc (LON:AZN) in a research note released on Monday morning. Goldman Sachs Group, Inc. (The) currently has a GBX 3,800 ($49.08) price objective on the biopharmaceutical company’s stock.

AZN has been the subject of a number of other research reports. HSBC Holdings plc reaffirmed a reduce rating and set a GBX 4,100 ($52.95) price objective on shares of AstraZeneca plc in a research note on Monday. UBS AG set a GBX 5,150 ($66.51) price objective on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Tuesday, June 27th. Barclays PLC reissued an overweight rating and set a GBX 5,500 ($71.03) target price on shares of AstraZeneca plc in a research report on Tuesday, August 1st. Citigroup Inc. reissued a buy rating and set a GBX 6,000 ($77.49) target price on shares of AstraZeneca plc in a research report on Friday, July 28th. Finally, Berenberg Bank increased their target price on shares of AstraZeneca plc from GBX 5,670 ($73.23) to GBX 5,850 ($75.55) and gave the stock a buy rating in a research report on Wednesday, May 17th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of Hold and an average price target of GBX 4,963.82 ($64.11).

Shares of AstraZeneca plc (LON:AZN) opened at 4901.00 on Monday. The firm’s market capitalization is GBX 62.05 billion. The firm’s 50 day moving average is GBX 4,571.40 and its 200-day moving average is GBX 4,878.32. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00.

AstraZeneca plc (LON:AZN) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the Zacks’ consensus estimate of $0.85 by $1.01. AstraZeneca plc had a net margin of 8.83% and a return on equity of 14.36%. On average, analysts expect that AstraZeneca plc will post $3.75 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “AstraZeneca plc’s (AZN) Sell Rating Reaffirmed at Goldman Sachs Group, Inc. (The)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/12/astrazeneca-plcs-azn-sell-rating-reaffirmed-at-goldman-sachs-group-inc-the.html.

The company also recently disclosed a dividend, which was paid on Monday, September 11th. Investors of record on Thursday, August 10th were paid a dividend of GBX 68.90 ($0.89) per share. This represents a yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th.

In other news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction that occurred on Thursday, July 27th. The shares were purchased at an average cost of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.